Top View
- (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
- Novel Treatment with Neuroprotective and Antiviral Properties Against a Neuroinvasive Human Respiratory Virus
- Clinically Actionable Pathways Identified in Individuals with Complex Disorders by Pharmacological Enrichment of Polygenic Risk
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Summary of the AOP
- (12) United States Patent (10) Patent No.: US 8,916,564 B2 Pettersson Et Al
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Blood-Brain Barrier in Drug Discovery : Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs / Edited by Li Di, Edward H
- Pharmaabkommen A1 E
- Why Did NMDA Receptor Antagonists Fail Clinical Trials for Stroke and Traumatic Brain Injury?
- Customs Tariff - Schedule Xxi - 1
- Failures and Successes of NMDA Receptor Antagonists
- Drug Repurposing to Treat Glucocorticoid Resistance in Asthma Alberta L
- Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
- Xenon: Neuroprotective Properties, Role in Anesthesia and Cadioprotection, Molecular Mechanisms of Action
- (12) Patent Application Publication (10) Pub. No.: US 2010/0226943 A1 Brennan Et Al
- Download Product Insert (PDF)
- Harmonized Tariff Schedule of the United States (2006) (Rev
- Characterization of the Discriminative Stimulus Effects of Nitrous Oxide
- Neuroprotective Strategies and the Underlying Molecular Basis of Cerebrovascular Stroke
- Molecular Mechanisms Transducing the Anesthetic, Analgesic, and Organ-Protective Actions of Xenon Benedikt Preckel, M.D., D.E.A.A.,* Nina C
- Failures and Successes of NMDA Receptor Antagonists
- (12) United States Patent (10) Patent No.: US 9,045,498 B2 Brodney Et Al
- Pharmaceutical Appendix to the Tariff Schedule 2
- The Role of Glutamate in Neuronal Ischemic Injury: the Role of Spark in fire
- Glycine Antagonist in Neuroprotection for Patients with Acute Stroke GAIN Americas: a Randomized Controlled Trial
- The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer’S Disease
- In the N-Methyl-D-Aspartate Receptor Glycine-Binding Site That Selectively Prevent Competitive Inhibition by Xenon Without Affecting Glycine Binding
- (12) Patent Application Publication (10) Pub. No.: US 2006/0270742 A1 Staunton Et Al